These findings confirm that the safety of [64Cu]Cu-NOTA-EV-F(ab’)2 in both GC and NSCLC models, reinforcing its potential for further clinical development of Nectin-4 targeting in cancer diagnosis and therapy. The gene discussed is NECTIN4; the disease is non-small cell lung carcinoma.